Company Overview and News

 
Don't Hold Your Breath For A THC Breathalyzer

2018-09-06 seekingalpha
Cannabix Technologies is a speculative stock, and current share price does not adequately reflect future risks.
BLOZF BLO

 
Cannabix Technologies Provides Technology Update on Marijuana Breathalyzer Development

2018-08-27 globenewswire
VANCOUVER, British Columbia, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that characterization work has demonstrated the ability to isolate ∆9-tetrahydrocannabinol (“THC”) and suppress background substrates effectively.
BLOZF BLO

 
Marijuana breathalyzer test aims to detect drivers who are high

2018-08-07 cnbc
A breathalyzer able to determine if a driver smoked pot could roll out in select cities in the fall, according to a company developing the first-of-its-kind product.
BLOZF BLO

 
Cannabix Technologies Comments on Bill C-46 – Unaware of any Material Change

2018-07-30 globenewswire
VANCOUVER, British Columbia, July 30, 2018 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc., (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) the developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace provides the following statement related to the government of Canada’s authorization of roadside saliva-testing devices under bill C-46: “It has been well signalled for some time by the Canadian government that a roadside saliva-testing device would be used when Canada legalizes marijuana later this year.
BLOZF BLO

3
Cannabix Technologies Provides Technology Update on Marijuana Breathalyzer Development

2018-06-18 globenewswire
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE:BLO) (OTC PINK:BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that recent testing with Beta 3.0 has shown the identification and first order separation of two key metabolites of ∆9-tetrahydrocannabinol (“THC”), being 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol in standards.
BLOZF BLO

4
Cannabix Technologies Files FAIMS Cannabis Detection Patent - Enters into License Agreement with University of Florida and Provides Technology Update

2018-04-16 globenewswire - 1
VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE:BLO) (OTC PINK:BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report it has filed a Patent Cooperation Treaty (“PCT”) application titled, “Device and Method for Detection of Cannabis and Other Controlled Substances Using FAIMS” (PCT/CA2017/000042).
BLOZF BLO

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...